Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.59 |
| ▸ | RARG | P13631 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19828517 | 1.00 | PPARG (0.69) | PPARGRXRACYP3A4FFAR1RARG | |
| SCHEMBL18541507 | 1.00 | PPARG (0.69) | PPARGRXRACYP3A4FFAR1RARG | |
| SCHEMBL14519307 | 0.89 | MAOB (0.57) | PPARGRXRACYP3A4FFAR1RARG | |
| SCHEMBL9803937 | 0.85 | PPARG (0.67) | PPARGRXRACYP3A4FFAR1RARG | |
| SCHEMBL7839014 | 0.84 | PPARG (0.64) | PPARGRXRACYP3A4FFAR1PPARA | |
| SCHEMBL12515224 | 0.84 | FFAR1 (0.69) | PPARGRXRACYP3A4FFAR1PPARA | |
| SCHEMBL8797615 | 0.84 | PPARG (0.72) | PPARGRXRACYP3A4FFAR1RARG | |
| SCHEMBL8196242 | 0.83 | PPARG (0.66) | PPARGRXRACYP3A4FFAR1PPARA | |
| SCHEMBL8792805 | 0.83 | PPARG (0.66) | PPARGRXRACYP3A4FFAR1PPARA | |
| Pioglitazone SCHEMBL28625431 | 0.83 | PPARG (0.98) | PPARGRXRACYP3A4FFAR1RARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999059586-A1 | THIAZOLIDINE AND OXAZOLIDINE DERIVATIVES FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION AND INHIBITION OF CARDIOMYOCYTE APOPTOSIS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0508740-B1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-01 | — | — | EP | claimed |
| US-5183823-A | PYRIDINE N-OXIDE COMPOUNDS WHICH ARE USEFUL AS HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | claimed |
| EP-0508740-A1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-14 | — | — | EP | claimed |
| US-4340605-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-07-20 | — | — | US | claimed |
| US-20220211682-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC | 2022-07-07 | — | — | US | disclosed |
| US-11123336-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | POXEL SA (FR) | 2021-09-21 | — | — | US | disclosed |
| US-10265305-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | POXEL SA (FR) | 2019-04-23 | — | — | US | disclosed |
| US-20180133204-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | POXEL SA (FR) | 2018-05-17 | — | — | US | disclosed |
| EP-2968298-B1 | DEUTERIUM-ENRICHED 2,4-THIAZOLIDINEDIONES AND METHODS OF TREATMENT | DEUTERX LLC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9833445-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170049762-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | POXEL SA (FR) | 2017-02-23 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| US-20070078170-A1 | Process for the preparation of pioglitazone | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-05 | — | — | US | disclosed |
| US-20070078170-A1 | Process for the preparation of pioglitazone | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-05 | — | — | US | disclosed |
| WO-1999059586-A1 | THIAZOLIDINE AND OXAZOLIDINE DERIVATIVES FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION AND INHIBITION OF CARDIOMYOCYTE APOPTOSIS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0508740-B1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-5183823-A | PYRIDINE N-OXIDE COMPOUNDS WHICH ARE USEFUL AS HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | disclosed |
| EP-0508740-A1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265305-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | SLC5A2, PPARD, DPP4 | PPARG 10/4885RXRA 213/4885CYP3A4 108/4885 |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | PPARG 2/4885RXRA 288/4885CYP3A4 10/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | PPARG 2/4885RXRA 309/4885CYP3A4 16/4885 |
| US-20220211682-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | PPARG 10/4885RXRA 213/4885CYP3A4 108/4885 |
| US-20070078170-A1 | Process for the preparation of pioglitazone | CYP3A5, CYP3A4, PPARD | PPARG 12/4885RXRA 462/4885CYP3A4 2/4885 |
| US-20180133204-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | PPARG 10/4885RXRA 213/4885CYP3A4 108/4885 |
| US-11123336-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | SLC5A2, PPARD, DPP4 | PPARG 10/4885RXRA 213/4885CYP3A4 108/4885 |
| US-20170049762-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | PPARG 10/4885RXRA 213/4885CYP3A4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.